Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljaf305 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Amy S Paller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital, Chicago, IL, USA. Hauptthemen laut MEDLINE: Psoriasis, Thalidomide, Anti-Inflammatory Agents, Non-Steroidal, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Oral treatment options for paediatric patients with moderate-to-severe plaque psoriasis are limited. In the 16-week double-blind placebo-controlled phase of the SPROUT trial, apremilast demonstrated efficacy vs. placebo in paediatric patients with psoriasis.
Objectives
To evaluate the 52-week efficacy and safety of apremilast in SPROUT.
Methods
SPROUT was a phase III multicentre randomized double-blind placebo-controlled parallel-group study (NCT03701763). Patients were randomized 2 : 1 to receive apremilast 20 or 30 mg (for patients weighing 20 to < 50 kg or ≥ 50 kg at baseline, respectively) twice daily or placebo for 16 weeks, after which all patients received apremilast through week 52 (apremilast/apremilast or placebo/apremilast, respectively). Patients were aged 6–17 years and had moderate-to-severe psoriasis that was inadequately controlled by or intolerant to topical therapy.
Results
Of 245 patients randomized, 221 (apremilast/apremilast, n = 149; placebo/apremilast, n = 72) entered the apremilast extension phase and 186 (apremilast/apremilast, n = 125; placebo/apremilast, n = 61) completed 52 weeks. With continued apremilast treatment, rates of static Physician Global Assessment (sPGA) response (score of 0 or 1 with ≥ 2-point reduction from baseline) further improved from week 16 (30.1%) to week 52 (47.7%). In the placebo/apremilast group, sPGA response rates increased from 9.8% at week 16 to 44.4% at week 52. The proportions of patients with ≥ 75% reduction from baseline in Psoriasis Area and Severity Index increased from 42.3% at week 16 to 60.4% at week 52 in the apremilast/apremilast group and from 13.4% to 63.9% in the placebo/apremilast group. No new safety signals were observed.
Conclusions
Improvements in clinical outcomes were sustained through 52 weeks with apremilast treatment in paediatric patients with moderate-to-severe psoriasis. Safety findings were consistent with the known safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital, Chicago, IL, USA.
- Stollery Children's Hospital University of Alberta, Edmonton, AB, Canada.
- Driscoll Children's Hospital, Corpus Christi, TX, USA.
- Hospital Universitario Marques de Valdecilla, Santander, Spain.
- Amgen Inc., Thousand Oaks, CA, USA.
- University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
ORCID-Profile: Amy S Paller, Loretta Fiorillo, Susana Armesto, Apostolos Kontzias, Rajneet K Oberoi, Lisa Arkin
Zitieren
APA
Paller, A. S., Fiorillo, L., Becker, E., Armesto, S., Kontzias, A., Oberoi, R. K., Zhang, W., Amouzadeh, H., Zhang, Z., & Arkin, L. (2025). Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf305
Vancouver
Paller AS, Fiorillo L, Becker E, Armesto S, Kontzias A, Oberoi RK, et al. Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf305
BibTeX
@article{Paller2025,
author = {Paller, Amy S and Fiorillo, Loretta and Becker, Emily and Armesto, Susana and Kontzias, Apostolos and Oberoi, Rajneet K and Zhang, Wendy and Amouzadeh, Hamid and Zhang, Zuoshun and Arkin, Lisa},
title = {Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljaf305}
}
EUVIMED